Education
About Us
Working with TipRanks
Follow Us
Milestone Pharmaceuticals (MIST)
NASDAQ:MIST
MIST Stock Chart & Stats
$1.87
-$0.02(-0.90%)
At close: 4:00 PM EST
$1.87
-$0.02(-0.90%)
Day’s Range― - ―
52-Week Range$0.63 - $3.06
Previous CloseN/A
Volume143.50K
Average Volume (3M)2.83M
Market Cap
$159.27M
Enterprise Value$157.01M
Total Cash (Recent Filing)$82.58M
Total Debt (Recent Filing)$57.21M
Price to Earnings (P/E)―
Beta2.19
Next Earnings
Mar 31, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding85,169,340
10 Day Avg. Volume2,418,746
30 Day Avg. Volume2,832,527
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)11.17
Price to Sales (P/S)0.00
P/FCF Ratio-5.08
Enterprise Value/Market Cap0.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-265.23
Enterprise Value/Ebitda-2.92
Forecast
1Y Price Target
$8.00Price Target Upside327.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.51
Revenue Forecast (FY)$37.95M
Bulls Say, Bears Say
Bulls Say
Commercial Launch ReadinessApproval would position the nasal spray as the first at-home, rapid treatment for PSVT, supporting planned sales hiring and prelaunch activities aimed at driving physician adoption and reducing emergency room visits.
Financing And RunwayMilestone-linked financing and recent equity proceeds provide significant funding upon approval and a cash runway into the first half of 2027 to support initial commercialization efforts.
Regulatory ProgressEuropean Medicines Agency acceptance of the marketing application advances the nasal spray toward potential EU approval, creating a new geographic revenue opportunity beyond the U.S.
Bears Say
Commercial Execution RiskChallenges in building and scaling an effective sales force and executing a new-product launch could slow market uptake and weaken early sales performance.
Intellectual Property And Funding UncertaintyIntellectual property uncertainty combined with the possibility that revenues fall short could create additional funding needs, increasing the risk of dilution or program delays.
Regulatory Risk For Label ExpansionRegulatory hurdles for developing additional indications such as atrial fibrillation could delay further approvals and limit near-term revenue growth from expanded uses.
Milestone Pharmaceuticals News
MIST FAQ
What was Milestone Pharmaceuticals’s price range in the past 12 months?
Milestone Pharmaceuticals lowest stock price was $0.63 and its highest was $3.06 in the past 12 months.
What is Milestone Pharmaceuticals’s market cap?
Milestone Pharmaceuticals’s market cap is $159.27M.
When is Milestone Pharmaceuticals’s upcoming earnings report date?
Milestone Pharmaceuticals’s upcoming earnings report date is Mar 31, 2026 which is in 53 days.
How were Milestone Pharmaceuticals’s earnings last quarter?
Milestone Pharmaceuticals released its earnings results on Nov 12, 2025. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.164 by $0.044.
Is Milestone Pharmaceuticals overvalued?
According to Wall Street analysts Milestone Pharmaceuticals’s price is currently Undervalued.
Does Milestone Pharmaceuticals pay dividends?
Milestone Pharmaceuticals does not currently pay dividends.
What is Milestone Pharmaceuticals’s EPS estimate?
Milestone Pharmaceuticals’s EPS estimate is -0.16.
How many shares outstanding does Milestone Pharmaceuticals have?
Milestone Pharmaceuticals has 85,169,340 shares outstanding.
What happened to Milestone Pharmaceuticals’s price movement after its last earnings report?
Milestone Pharmaceuticals reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.164. Following the earnings report the stock price went up 1.047%.
Which hedge fund is a major shareholder of Milestone Pharmaceuticals?
Currently, no hedge funds are holding shares in MIST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Milestone Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.00 (327.81% Upside)
$8.00 (327.81% Upside)
Blogger Sentiment
Bullish
MIST Sentiment 70%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 6.2%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-6.03%
12-Months-Change
Fundamentals
Return on Equity
-260.65%
Trailing 12-Months
Asset Growth
6.10%
Trailing 12-Months
Company Description
Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
MIST Stock 12 Month Forecast
Average Price Target
$8.00
▲(327.81% Upside)
Technical Analysis
Corbus Pharmaceuticals
―
Seres Therapeutics
―
Avalo Therapeutics
―
Elicio Therapeutics
―
Alto Neuroscience, Inc.
―
Ownership Overview
0.91% Insiders
0.02% Mutual Funds
0.03% Other Institutional Investors
97.21% Public Companies and
Individual Investors